# Beijing Immunoah Pharma Tech

Source: https://onco.cc/companies/immunoah/  
OnCo record `immunoah` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beijing Immunoah develops antibodies that switch on the immune system against cancer, including antibodies that bind two or three targets at once. Its first registered study tests an injection given directly into tumours in advanced solid cancers.

## Summary

Beijing Immunoah Pharma Tech Co., Ltd. (Beijing Immune Ark Medical Technology) was founded in 2017, according to the company, by Xin Gao, with a sister company in Denver. It focuses on agonist antibodies for cancer immunotherapy and on multi-specific antibodies built on its XFab platform; its history lists licensing agreements for 4-1BB (2017), CD40 (2018) and OX40 (2019) agonist antibodies, a first tri-specific antibody proof of concept in 2020 and a pre-A financing round in December 2020. Its registered phase 1a trial, NCT06292858, tests IMB071703 given by intratumoral injection in recurrent or metastatic advanced solid tumours at a site in Shanghai, with a start date of February 2023. Its first registered cancer trial, NCT06292858, was posted on ClinicalTrials.gov in March 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Immunoah; Beijing Immune Ark Medical Technology; Beijng Immunoah Pharma Tech Co., Ltd.
- HQ: Beijing
- Type: biotech
- Website: http://www.immunoah.cn/

## Notes

- The target of IMB071703 is not stated on the company website or the registry record; the target links reflect the agonist antibody programmes in the company's history, not IMB071703 specifically.
- The English site (en.immunoah.cn) was read over plain HTTP on 29 October 2026; the HTTPS address returned a certificate for another host.
- No financing amount is stated.

## Sources

- Official website: http://www.immunoah.cn/
- Company profile and history (English): http://en.immunoah.cn/aboutus1.html
- ClinicalTrials.gov: phase 1a trial of IMB071703 (NCT06292858): https://clinicaltrials.gov/study/NCT06292858

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/), [CD40](https://onco.cc/targets/cd40/), [OX40 (TNFRSF4)](https://onco.cc/targets/tnfrsf4/)

---
JSON: https://onco.cc/api/v1/entities/immunoah.json